Neue Novavax: Anstieg nach 1:20 Re-Split

Handel für Novavax war eben für kurze Zeit sogar angehalten.  

Novavax capitalizing on stock bump following coronavirus vaccine news.

The Gaithersburg biotech has raked in $98.7 million in net proceeds this quarter from selling 10.5 million shares of common stock at $9.55 per share....


www.bizjournals.com/washington/news/2020/...oo&yptr=yahoo

Nachdem Novavax zu den auserwählten Unternehmen gehören, die von Trump im Weißen Haus empfangen wurden, um über Corona zu beraten. War immerhin ne illustre Runde mit J&J, Sanofi, Gilead (Forty Seven), ect...

old.nasdaq.com/de/symbol/nvax/real-time

President Trump Meeting With Pharmaceutical Executives on Coronavirus

www.c-span.org/video/?469926-1/...ical-executives-coronavirus

We didn't invest in Novavax for the Coronavirus. I could care less. Nanoflu destroyed Fluzone HD in phase 2 so Phase 3 should be a cake walk. What can actually change in the results? The Nanoparticle with the Matrix M adjuvant is a powerhouse! I'm going to say this. Novavax has created a WORLDWIDE well needed flu drug! $12.48? This is like free money! Invest invest and invest! Less than 30 days the ROI will be outstanding.

Ich lehne mich jetzt mal weit aus dem Fenster und sage, genau so wird es kommen, imho.

Kommentar aus dem Yahoo Finance Forum: Wir haben nicht in Novavax für das Coronavirus investiert. Es könnte mich weniger interessieren. Nanoflu zerstörte Fluzone HD in Phase 2, daher sollte Phase 3 ein Kinderspiel sein. Was kann sich tatsächlich an den Ergebnissen ändern? Das Nanopartikel mit dem Matrix M-Adjuvans ist ein Kraftpaket! Ich werde das sagen. Novavax hat ein weltweit benötigtes Grippemedikament entwickelt! 12,48 $? Das ist wie freies Geld! Investieren investieren und investieren! In weniger als 30 Tagen ist der ROI hervorragend.

Hier mal noch eine Einschätzung von heute von Keith Speights
(TMFFishBiz):

"There's no way to know for sure which of these biotech stocks will be the bigger winner over the long run. If I had to pick just one of them, though, it would be Novavax.

Inovio does appear to have a slight lead with its coronavirus program. However, Novavax has a major catalyst coming up in a matter of weeks with the announcement of results for NanoFlu. My view is that Novavax has a reasonable chance of getting a product on the market much sooner than Inovio does.

Keep in mind, though, that both of these stocks are very risky. Their experimental COVID-19 vaccines and their other pipeline candidates could flop in clinical studies. While I think Novavax has the edge right now, it's best to be very cautious when investing in clinical-stage biotechs."

Es ist nicht sicher, welche dieser Biotech-Aktien auf lange Sicht der größere Gewinner sein wird. Wenn ich nur einen auswählen müsste, wäre es Novavax. Inovio scheint mit seinem Coronavirus-Programm einen leichten Vorsprung zu haben. Novavax hat jedoch innerhalb weniger Wochen mit der Bekanntgabe der Ergebnisse für NanoFlu einen wichtigen Katalysator vor sich. Meiner Ansicht nach hat Novavax eine vernünftige Chance, ein Produkt viel früher auf den Markt zu bringen als Inovio. Beachten Sie jedoch, dass beide Aktien sehr riskant sind. Ihre experimentellen COVID-19-Impfstoffe und ihre anderen Pipeline-Kandidaten könnten in klinischen Studien versagen. Ich denke, Novavax hat momentan die Nase vorn, aber es ist am besten, sehr vorsichtig zu sein, wenn Sie in Biotech-Unternehmen im klinischen Stadium investieren.

Novavax Awarded Funding from CEPI for COVID-19 Vaccine Development

-CEPI to provide an initial $4 million to accelerate vaccine development to prepare for Phase 1

-Multiple vaccine candidates being tested in preclinical studies prior to advancing to human trials

-Phase 1 clinical trial expected to initiate in late spring of 2020

ir.novavax.com/news-releases/...i-covid-19-vaccine-development

muss erstmal getestet werden. Und das macht nun NanoRepro....

Novavax and Serum Institute of India to Develop and Commercialize Malaria Vaccine Candidate

finance.yahoo.com/news/...titute-india-develop-144548684.html

Oppenheimer Backs Novavax as a Coronavirus Play

finance.yahoo.com/news/...vax-coronavirus-play-190117201.html

und da sind sie:

Novavax’ NanoFlu Achieves All Primary Endpoints In Phase 3 Clinical Trial

These strong Phase 3 results align with and validate our previous clinical trials, in which NanoFlu showed higher HAI antibody responses than the leading flu vaccine for older adults.

ir.novavax.com/news-releases/...ary-endpoints-phase-3-clinical

mit seinem breiten Profil nicht auch gegen Coronaviren funktioniert ^^

Jetzt kommt es auf das Management an alle weiteren Schritte richtig zu wählen.

Novavax price target raised to $24 from $17 at H.C. Wainwright 07:26 NVAX H.C. Wainwright analyst Vernon Bernardino raised the firm's price target on Novavax to $24 from $17 and reiterates a Buy rating on the shares. The stock closed Tuesday up 19% to $12.77. Novavax yesterday announced positive top-line results from its pivotal Phase 3 clinical trial with NanoFlu, the company's Matrix-M adjuvanted recombinant quadrivalent seasonal influenza vaccine candidate for adults aged 65 and older, Bernardino tells investors in a research note. The results are impressive, as they clearly show better immunogenic responses are stimulated by NanoFlu versus the market-leading quadrivalent seasonal influenza vaccine, says the analyst. Bernardino believes the data create a clear path to FDA licensure.

Read more at:
thefly.com/landingPageNews.php?id=3059689

Novavax price target raised to $23 from $16 at Cantor Fitzgerald

Read more at:
thefly.com/landingPageNews.php?id=3059696

Novavax plans FDA filing after NanoFlu trumps Sanofi flu vaccine
26th March 2020
Image


by

Anna Smith

Novavax has unveiled new Phase III data showing that its recombinant quadrivalent seasonal influenza vaccine candidate, NanoFlu, met all primary endpoints in adults aged 65 and older against Sanofi’s Fluzone Quadrivalent.

As a results of the successful data, the company has announced plans to submit a filing to the US Food and Drug Administration (FDA) under the agency's accelerated approval pathway.

In the trial, geometric mean titers (GMT) at day 28 for NanoFlu were 24% to 66% higher than for Fluzone Quadrivalent, while the experimental vaccine was associated with 11.4 to 20.4 higher seroconversion rates (SCR) percentage points than the Sanofi drug.

Top-line results showed that NanoFlu achieved the primary endpoints, using both GMT and SCR, for all four strains included in the vaccine, as measured by haemagglutination inhibition (HAI) assays using egg-derived reagents.

According to the company, NanoFlu was also well tolerated in the Phase III study and had a safety profile comparable to Fluzone Quadrivalent, but was associated "with a modest increase in local adverse events."

Last year Novavax announced that its respiratory syncytial virus vaccine ResVax failed to hit its main goal, despite showing efficacy against a secondary objective, preventing RSV LRTI hospitalisations by 44%.
Share

Heute neuer Anlauf - $15

ih.advfn.com/...p;width=800&vol=1&height=400&Vol=1

mit den 15$
de.advfn.com/borse/NASDAQ/NVAX/chart

Hut ab , bist du Hellseher oder hast du Insiderwissen
nachbörslich tatsächlich noch die  15$ angekratzt

de.advfn.com/borse/NASDAQ/NVAX/chart